Holen Sie sich die Stockscreener-App
3.75
5.06%
-0.20
Handel nachbörslich:
3.75
Schlusskurs vom Vortag:
$3.95
Offen:
$3.94
24-Stunden-Volumen:
6,167
Relative Volume:
0.20
Marktkapitalisierung:
$177.77M
Einnahmen:
$27,600
Nettoeinkommen (Verlust:
$-36.04M
KGV:
-4.7063
EPS:
-0.7968
Netto-Cashflow:
$-1.66M
1W Leistung:
-6.95%
1M Leistung:
+15.38%
6M Leistung:
-21.05%
1J Leistung:
-40.48%
1-Tages-Spanne:
$3.68
$3.94
1-Wochen-Bereich:
$3.60
$4.00
52-Wochen-Spanne:
$2.76
$7.51
Nanobiotix Adr Stock (NBTX) Company Profile
Vergleichen Sie NBTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBTX
Nanobiotix Adr
|
3.75 | 177.77M | 27,600 | -36.04M | -1.66M | -0.7968 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nanobiotix Adr Stock (NBTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-28 | Eingeleitet | Guggenheim | Buy |
| 2023-12-08 | Eingeleitet | Leerink Partners | Outperform |
| 2021-01-06 | Eingeleitet | Evercore ISI | Outperform |
Nanobiotix Adr Aktie (NBTX) Neueste Nachrichten
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study - MSN
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Mexico Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Latin America Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Middle East & Africa Chitosan Market Size & Outlook, 2030 - Grand View Research
The United States Chitosan Market Size & Outlook, 2030 - Grand View Research
China Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
Japan Chitosan Market Size & Outlook, 2022-2030 - Grand View Research
symbol__ Stock Quote Price and Forecast - CNN International
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
Finanzdaten der Nanobiotix Adr-Aktie (NBTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):